Get the Stockscreener App
1.99
6.42%
0.12
After Hours:
1.98
-0.01
-0.50%
Milestone Pharmaceuticals Inc stock is traded at $1.99, with a volume of 306.84K.
It is up +6.42% in the last 24 hours and up +39.16% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.87
Open:
$1.91
24h Volume:
306.84K
Relative Volume:
1.13
Market Cap:
$106.12M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.4526
EPS:
-1.37
Net Cash Flow:
$-46.54M
1W Performance:
+8.15%
1M Performance:
+39.16%
6M Performance:
+27.56%
1Y Performance:
-35.60%
1-Day Range:
$1.90
$2.00
1-Week Range:
$1.83
$2.00
52-Week Range:
$1.12
$3.52
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.99 | 106.12M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Sudden Hearing Loss Study Reaches Milestone: AudioCure Pharma Enrolls More Than Half of the Patients in AC102 Study - Yahoo Finance
Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright - MSN
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval - The Globe and Mail
Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Yahoo Finance
Seres Therapeutics Q3 2024 Earnings Preview - MSN
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaViaReflecting the Company's Focus on Cardiometabolic Diseases - Yahoo Finance
Milestone Pharmaceuticals Inc. (MIST) Quarterly 10-Q Report - Quartzy
Milestone Pharmaceuticals: Q3 Earnings Snapshot - Darien Times
Gyre Therapeutics Revenue Falls 20% as Phase 3 Trial Milestone Nears Critical Data | GYRE Stock News - StockTitan
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone Pharma Trims Losses 38% as CARDAMYST Shows Strong Phase 3 Results in China | MIST Stock News - StockTitan
BridgeBio's Acoramidis Nears FDA Approval; $500M Milestone Payment Awaits | BBIO Stock News - StockTitan
Armata Pharmaceuticals Hits Key Milestone in Bacteriophage Therapy Trial, Eyes 2025 Data | ARMP Stock News - StockTitan
Royalty Pharma Reports Third Quarter 2024 Results - ForexTV.com
Argenica Therapeutics' Phase 2 stroke drug trial hits major milestone - Proactive Investors USA
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet? - Simply Wall St
Head to Head Analysis: Milestone Pharmaceuticals (NASDAQ:MIST) & Alkermes (NASDAQ:ALKS) - Defense World
InnoCare Pharma (SEHK:9969) Achieves Key Milestone with ICP-488 Phase II Success in Psoriasis Treatment - Yahoo Finance
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
CNSPCNS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Creso Pharma Limited Exceeds Milestone of 3 Million Anibidiol® Doses Sold in Europe - Marketscreener.com
Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies - Marketscreener.com
FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships - Yahoo Finance
MSD acquires cancer therapeutics developer Modifi Biosciences - Pharmaceutical Technology
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - BioSpace
Biotech stock tumbles after unexplained 1,446% gain - MSN
Candel therapeutics investor sells $243,834 in stock By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC Wainwright - MarketBeat
Wainwright maintains Buy rating on Milestone Pharma stock By Investing.com - Investing.com UK
Millennium Management LLC Sells 105,682 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46% - Yahoo Finance
IRLAB Receives Milestone Payment of USD 2.5 million in Conjunction with First Dosing in a Phase I Study with IRL757 in Healthy Older Adults - Yahoo Finance
OKUR stock soars to all-time high, reaching $20 milestone - Investing.com
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 - MyChesCo
1 AI Biotech Stock That Just Scored a Major Milestone - TradingView
1 AI Biotech Stock That Just Scored A Major Milestone - Barchart
Antiarrhythmic Drugs Market Size And Share Report, 2030 - Grand View Research
Candel therapeutics insider sells shares worth over $240k - Investing.com
Scientech Research LLC Invests $289,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Susquehanna Fundamental Investments LLC Makes New Investment in Boston Scientific Co. (NYSE:BSX) - Defense World
MP Materials (NYSE:MP) PT Raised to $23.00 - Defense World
ProShare Advisors LLC Raises Stock Holdings in Bruker Co. (NASDAQ:BRKR) - Defense World
Toronto Dominion Bank Has $2.66 Million Position in Veeva Systems Inc. (NYSE:VEEV) - Defense World
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Sees Large Increase in Short Interest - MarketBeat
NRX-100 (Ketamine) Reaches Stability Milestone - Contract Pharma
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine) - StockTitan
Milestone Pharmaceuticals to Host Investor KOL Event - StockTitan
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement - Yahoo Finance
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 0.7% Higher - Defense World
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):